Subsequent loss of AXIN1 in RUNX1-deficient ER+ breast cancer cells may be prevented by treatment with tankyrase inhibitors64, 65 (Fig. 7), partly alleviating consequences of RUNX1 loss. This evidence concerns the gene AXIN1 and breast carcinoma.